Daito Pharmaceutical Co., Ltd. · TSE:4577

Daito Pharmaceutical — Q1 FYE May 2027 Earnings Presentation

12 slides from Daito Pharmaceutical's earnings presentation, Oct 14, 2026

  1. Slide 1: FY2027 1Q Earnings Presentation

    Fiscal Year Ending May 2027 FY2027 1Q Earnings Presentation October 14, 2026 (Wed) Daito Pharmaceutical Co., Ltd. Copyright Daito Pharmaceutical Copyright Daito Co., Ltd. Pharmaceutical Co., Ltd.

  2. Slide 2: Contents

    Contents I. Financial Results Summary for 1Q FYE May 2027 p. 3 II. Transfer of KYORIN Pharmaceutical's Generic p. 10 Drug Business Copyright Daito Pharmaceutical Co., Ltd. 2

  3. Slide 3: I. Financial Results Summary for 1Q FYE May 2027

    I. Financial Results Summary for 1Q FYE May 2027 Copyright Daito Pharmaceutical Co., Ltd. 3

  4. Slide 4: Executive Summary

    I. Financial Results Summary for 1Q FYE May 2027 Executive Summary 1Q Fiscal Year Ending May 2027 ◼ Consolidated net sales were 11.89 billion yen, a decrease of 8.6% YoY, and EBITDA was 1.68 billion yen, a decrease of 17.3% YoY, but both exceeded management expectation. ◼ Although operating and ordi

  5. Slide 5: Financial Highlights

    I. Financial Results Summary for 1Q FYE May 2027 Financial Highlights ◼ Net sales declined for both APIs and FDF products, a YoY decrease of 1.16 billion yen, or 8.6% ◼ Regarding profits, although SG&A expenses decreased due to the timing of R&D cost recognition being pushed back, operating profit d

  6. Slide 6: Sales by Category

    I. Financial Results Summary for 1Q FYE May 2027 Sales by Category ◼ APIs declined due to temporary inventory adjustments at major customers and the timing of orders for certain items, resulting in a decrease of 650 million yen, or 10.8% ◼ FDF products saw a significant increase in contract-manufact

  7. Slide 7: Analysis of Changes in Operating Profit

    I. Financial Results Summary for 1Q FYE May 2027 Analysis of Changes in Operating Profit (Millions of yen) 998 Other costs, etc. 138 712 Change in net sales, product mix, etc. △291 R&D cost Impact of foreign exchange 134 Depreciation Utility expenses △80 67 △3 Impact of Personnel expenses • Signific

  8. Slide 8: Balance Sheet Summary

    I. Financial Results Summary for 1Q FYE May 2027 Balance Sheet Summary ◼ In addition to the inventory level being temporarily low at the end of May, Daito proceeded with securing inventory in anticipation of sales demand, resulting in an increase in inventories of 1.85 billion yen, or 11.1%. ◼ Refle

  9. Slide 9: Cash Flows Statement Summary

    I. Financial Results Summary for 1Q FYE May 2027 Cash Flows Statement Summary ◼ Operating CF increased significantly by 1.10 billion yen, or 64.5% YoY, as the collection of trade receivables from the strong sales in 4Q of the previous fiscal year progressed, despite an increase in inventories. ◼ Inv

  10. Slide 10: II. Transfer of KYORIN Pharmaceutical's Generic Drug Business

    II. Transfer of KYORIN Pharmaceutical's Generic Drug Business Copyright Daito Pharmaceutical Co., Ltd. 10

  11. Slide 11: Overview (1) Scheme and Inherited Assets of this Transaction

    II. Transfer of KYORIN Pharmaceutical's Generic Drug Business Overview (1) Scheme and Inherited Assets of this Transaction About this Scheme (I) Current Status (II) Absorption-type Company Split (III) Share Transfer (Scheduled for March 31, 2027) (Scheduled for April 1, 2027) Implementation of an ab

  12. Slide 12: Overview (2) Pharmatech Co-creation Platform, Inc. and Future Schedule

    II. Transfer of KYORIN Pharmaceutical's Generic Drug Business Overview (2) Overview of the Pharmatech Co-creation Platform, Inc. and Future Schedule Introduction of the Representative Director (Planned) Overview of the Pharmatech Co-creation Platform, Inc. appointed by Daito ◼ Appointed a leader wit

Daito Pharmaceutical — Q1 FYE May 2027 Earnings Presentation on 6ix